Aduro Biotech Appoints Thomas Dubensky, Jr. as Chief Scientific Officer
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announced today its appointment of Thomas Dubensky, Jr., Ph.D. as Chief Scientific Officer. Dr. Dubensky is reuniting with the vaccine program that he helped to initiate in 2002, when he was Vice President of Research at Cerus Corporation. The vaccine program is based on Listeria monocytogenes (Listeria), which was selected as a vector for development of clinical vaccine candidates based on potency comparisons with several alternative vector platforms. First at Cerus and subsequently at Anza Therapeutics, Dr. Dubensky led the development of the live-attenuated double deleted Listeria (LADD) vaccine platform, which formed the basis for three distinct therapeutic vaccine candidates that were evaluated in three FDA-approved Phase 1 clinical trials.